The biomedic industry has achieved a positive year in 2024, as drug developers continued to obesity in the scene. I reported 19 of the 20 best companies affiliated with global biological pharmaceutical companies that were generally circulated about the growth of revenue, which led to an increase of more than 7.9 % in total revenues, up to 880.4 billion dollars from 2023 to 2024, according to Globaldata, a leading data and analysis company.
ELI Lilly witnessed the highest growth in revenue by 32 % to $ 45 billion in 2024, followed by Novo Nordisk by 25.5 % to 42.1 billion dollars. This revenue growth is provided with strong successes in obesity and diabetes in diabetes. ELI Lilly’s Mounjaro (Tirzepatide) and Zepbound (Tirzepatide) were born with a total global sales of $ 16.5 billion in 2024, while Novo Nordisk’s OzemPIC (Semaglutide) and Wegovy (SEMAGLUTIDE) made its global sales of up $ 25.9 billion. The growth of Eli Lili’s revenue was driven by the ABEMACICLIB breast cancer, which recorded global sales of $ 5.3 billion in 2024. The revenue growth gap between the two companies from the long -term market share of Novo Nordisk and Wegovy is expected. Eli Lily is expected to see revenue growth of 34.3 % to $ 59.2 billion in 2025, while Novo Nordsek is expected to witness only 16.4 % revenue growth to 47.7 billion dollars in 2025, according to sales databases and forecasting in Globalata.
Astellas Parma also showed a strong performance with a growth of 19.2 % to $ 13.2 billion, driven by XTandi (Enzalutamide) sales of prostate cancer, which recorded global sales of $ 5.98 billion in 2024.
Vizar and Rush Both witnessed a recovery in revenue after their sales decreased in the previous year, driven by the decline in demand for Covid-19 products. PFIZER revenues grew by 6.8 % to $ 63.6 billion in 2024, and Roche’s revenues grew by 3 % to $ 68.7 billion in the same year. Paxlovid at Covid-19 of Pfizer-19 saw an unprecedented return in sales of 347 % in sales to $ 5.7 billion in 2024, driven by strong demand in the United States. However, the recovery of PFIZER sales after birth is increasingly turning towards its unborn products, led by Eliquis (APIXABAN), which achieved $ 13.3 billion of global sales in 2024. The company is preparing for more revenue growth from December 2023 opinionWith medicines that are marketed by PadCev (Enformumab Vedotin), Adcetris (Brentuximab Vedotin), Tukysa (Tucatinib), TIVDAK (TISOTUMAB Vedotin) and Aidexi (Disitamab Vedotin) to achieve integrated global sales of $ 8 billion.
10 of the 20 best companies exceeded 10 % on an annual basis (YOY) in its operational profits in 2024: PFIZER (1,134.1 %), Merck & Co (1,017.1 %), ELI Lilly (99.7 %) and ASTELLAS Parma (52.5 %) from more than 50 % growth. The huge increase in Pfizer in its operating profit was attributed to initiatives to reduce the continuous costs that provided $ 4.5 billion. Meanwhile, the strong success of Merck & Co’s Keytruda (Pembrolizumab) has increased the growth profit growth of 1,017.1 %. It has been further strengthened by lower property rights rates and lower research and development expenses (R&D). but, Bristol Mairescape (-171.7 %), Bayer (-111.6 %), and Glyid science (-78.1 %) was 50 % decreased in their operating profits.
https://media.zenfs.com/en/pharmaceutical_technology_376/65cd61a220f52413f6fdbfed48469d10
Source link